CD274 and neoplasm: Since the tumor immune microenvironment showed a distinct difference between the two risk groups, the response of ICI was also predicted using the IMvigor210 cohort, a cohort of platinum-treated locally advanced or metastatic urothelial carcinoma (mUC) patients receiving anti-PD-L1 immunotherapy.